PD L1 News and Research

RSS

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

Thanks to advances in cancer therapies, most forms of breast cancer are highly treatable, especially when caught early.

15 Dec 2022

AI could make doctors’ work simpler, faster, and more precise

One in nine women in the developed world will be diagnosed with breast cancer at some point in her life. The prevalence of breast cancer is increasing, an effect caused in part by the modern lifestyle and increased lifespans.

2 Dec 2022

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

28 Oct 2022

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

An article published in Science Advances suggests that a type of cancer treatment known as immune checkpoint blockade may be beneficial in certain cases of severe COVID-19.

27 Oct 2022

Researchers circumvent a key mechanism in castration-resistant prostate cancer

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that they can circumvent a key mechanism in castration-resistant prostate cancer (CRPC) and possibly make immunotherapies more effective.

20 Oct 2022

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).

20 Sep 2022

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.

13 Sep 2022

Research could lead to a new therapeutic option for patients with bladder cancer

Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system.

12 Sep 2022

Researchers synthesize a small molecule that can be used to treat a range of cancers

Researchers at Tel Aviv University and the University of Lisbon have jointly identified and synthesized a small molecule that could be a more accessible and effective alternative to an antibody that is successfully used to treat a range of cancers.

8 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression of at least one percent. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these two combinations have an added benefit for patients in comparison with chemotherapy alone.

8 Aug 2022

Genetic signatures may help predict immunotherapy response in patients with bladder cancer

Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy.

3 Aug 2022

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

2 Aug 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Healthy, cancer, and immunosuppressed patients all benefit from COVID boosters

In a recent study posted to the medRxiv* pre-print server, researchers developed a mechanistic mathematical model to predict the course of vaccine-induced immunity in healthy and immunosuppressed patients for the long term, exceeding the time frames for which clinical data is currently available.

5 Jul 2022

Researchers fabricate highly-sensitive SERS probes to detect the PD-L1 biomarker

Recently, a team led by Prof. Huang Qing at the Institute of Intelligent Machines, Hefei Institutes of Physical Science (HFIPS) of Chinese Academy of Sciences (CAS) have reported the fabrication of ultrasensitive biosensors based on Surface-enhanced Raman Spectroscopy (SERS) to detect the cancer metastasis related programmed death ligand (PD-L1) biomarker.

1 Jul 2022

New study looks at the role of beta cells in triggering autoimmunity

Research into the causes of type 1 diabetes often focuses on the autoimmune response, where the immune system destroys pancreatic islet beta cells that produce insulin.

28 Jun 2022

New nanoparticles effectively stopped the growth and spread of ovarian, liver tumors in mice

As they grow, solid tumors surround themselves with a thick, hard-to-penetrate wall of molecular defenses. Getting drugs past that barricade is notoriously difficult.

24 Jun 2022

PD L1 News and Research

Researchers discover how certain breast cancers persist after chemo and do not respond to immunotherapies

AI could make doctors’ work simpler, faster, and more precise

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

Immune checkpoint therapy may be beneficial in certain cases of severe COVID-19

Researchers circumvent a key mechanism in castration-resistant prostate cancer

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

Study highlights role of tumor-infiltrating B cells, plasma cells in cancer development and treatment outcomes

Research could lead to a new therapeutic option for patients with bladder cancer

Researchers synthesize a small molecule that can be used to treat a range of cancers

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Genetic signatures may help predict immunotherapy response in patients with bladder cancer

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

Cytokine-based cancer immunotherapy: current progress and future prospects

Healthy, cancer, and immunosuppressed patients all benefit from COVID boosters

Researchers fabricate highly-sensitive SERS probes to detect the PD-L1 biomarker

New study looks at the role of beta cells in triggering autoimmunity

New nanoparticles effectively stopped the growth and spread of ovarian, liver tumors in mice

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News